Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
The arrival of GLP-1 medications has completely transformed the landscape of metabolic health and weight management. For years, patients relied on weekly injections to experience the fantastic benefits of treatments like semaglutide. The introduction of a daily oral formulation under…
Novo Nordisk recently raised its profit goals for the year. This change comes because many people want the new Wegovy pill. Doctors wrote over 1.3 million prescriptions in just three months. By middle April, that number grew to over 2…
The Food and Drug Administration approved (FDA) once-daily oral Wegovy tablets. Novo Nordisk launched this prescription medication nationally in January 2026. Retail pharmacies and select telehealth platforms simultaneously offer the pill. Patients, consequently, gain a noninjectable alternative for chronic weight…
Healthcare providers are currently witnessing a major shift toward oral delivery systems for treating chronic weight conditions. The FDA approved the daily 25 mg semaglutide (Wegovy) tablet for obesity in late 2025. In view of this, the oral formulation provides…